Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

1081. Detection, adherence and control of hypertension for the prevention of stroke: a systematic review

Detection, adherence and control of hypertension for the prevention of stroke: a systematic review Detection, adherence and control of hypertension for the prevention of stroke: a systematic review Detection, adherence and control of hypertension for the prevention of stroke: a systematic review Ebrahim S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Ebrahim S. Detection, adherence and control of hypertension for the prevention of stroke: a systematic review. Health Technology Assessment 1998; 2(11): 1-78 Authors' objectives The objectives were to find out the most effective methods of: detecting hypertension improving patient adherence with treatment improving control of blood pressure improving professional compliance with standards of good practice. Authors' conclusions Implications for health care Policy and practice

Health Technology Assessment (HTA) Database.1998

1082. Detection, adherence and control of hypertension for the prevention of stroke: a systematic review

Detection, adherence and control of hypertension for the prevention of stroke: a systematic review Detection, adherence and control of hypertension for the prevention of stroke: a systematic review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search

NIHR HTA programme1998

1083. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. 9504938 1998 03 19 1998 03 19 2014 11 20 0028-4793 338 12 1998 Mar 19 The New England journal of medicine N. Engl. J. Med. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. 784-90 Endothelin is a powerful vasoconstrictor peptide derived (...) from the endothelium. We evaluated the contribution of endothelin to blood-pressure regulation in patients with essential hypertension by studying the effect of an endothelin-receptor antagonist, bosentan. We studied 293 patients with mild-to-moderate essential hypertension. After a placebo run-in period of four to six weeks, patients were randomly assigned to receive one of four oral doses of bosentan (100, 500, or 1000 mg once daily or 1000 mg twice daily), placebo, or the angiotensin

NEJM1998

1084. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group.

Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. 9515998 1998 03 26 1998 03 26 2016 10 17 0098-7484 279 11 1998 Mar 18 JAMA JAMA Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. 839-46 (...) Nonpharmacologic interventions are frequently recommended for treatment of hypertension in the elderly, but there is a paucity of evidence from randomized controlled trials in support of this recommendation. To determine whether weight loss or reduced sodium intake is effective in the treatment of older persons with hypertension. Randomized controlled trial. A total of 975 [corrected] men and women aged 60 to 80 years with systolic blood pressure lower than 145 mm Hg and diastolic blood pressure lower than 85

JAMA1998

1085. Effect of treatment of isolated systolic hypertension on left ventricular mass.

Effect of treatment of isolated systolic hypertension on left ventricular mass. 9508155 1998 03 19 1998 03 19 2016 11 24 0098-7484 279 10 1998 Mar 11 JAMA JAMA Effect of treatment of isolated systolic hypertension on left ventricular mass. 778-80 Left ventricular (LV) hypertrophy is a common problem among elderly patients with isolated systolic hypertension (ISH), but the effect of treatment of ISH on LV mass is not known. To assess the ability of antihypertensive drug treatment to reduce LV (...) mass in ISH. Echocardiographic Substudy of the Systolic Hypertension in the Elderly Program (SHEP). A total of 104 participants at the St Louis SHEP site who had interpretable baseline echocardiograms, 94 of whom had 3-year follow-up echocardiograms. The SHEP participants were randomized to placebo or active treatment with chlorthalidone (12.5-25 mg/d), with atenolol (25-50 mg/d) added if necessary to maintain goal blood pressure. Change in LV mass assessed by echocardiography. Minimum follow-up

JAMA1998

1086. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 9635947 1998 07 10 1998 07 10 2015 06 16 0140-6736 351 9118 1998 Jun 13 Lancet (London, England) Lancet Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 1755-62 (...) Despite treatment, there is often a higher incidence of cardiovascular complications in patients with hypertension than in normotensive individuals. Inadequate reduction of their blood pressure is a likely cause, but the optimum target blood pressure is not known. The impact of acetylsalicylic acid (aspirin) has never been investigated in patients with hypertension. We aimed to assess the optimum target diastolic blood pressure and the potential benefit of a low dose of acetylsalicylic

Lancet1998

1087. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. 9486993 1998 03 05 1998 03 05 2013 11 21 0028-4793 338 10 1998 Mar 05 The New England journal of medicine N. Engl. J. Med. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. 645-52 It has recently been reported that the use of calcium-channel blockers (...) for hypertension may be associated with an increased risk of cardiovascular complications. Because this issue remains controversial, we studied the incidence of such complications in patients with non-insulin-dependent diabetes mellitus and hypertension who were randomly assigned to treatment with either the calcium-channel blocker nisoldipine or the angiotensin-converting-enzyme inhibitor enalapril as part of a larger study. The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial is a prospective

NEJM1998

1088. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. 9732339 1998 10 28 1998 10 28 2016 11 24 0959-8138 317 7160 1998 Sep 12 BMJ (Clinical research ed.) BMJ Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. 720-6 To estimate the economic efficiency of tight blood pressure control (...) , with angiotensin converting enzyme inhibitors or beta blockers, compared with less tight control in hypertensive patients with type 2 diabetes. Cost effectiveness analysis incorporating within trial analysis and estimation of impact on life expectancy through use of the within trial hazards of reaching a defined clinical end point. Use of resources driven by trial protocol and use of resources in standard clinical practice were both considered. 20 hospital based clinics in England, Scotland, and Northern

BMJ1998 Full Text: Link to full Text with Trip Pro

1089. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. 9802273 1998 11 17 1998 11 17 2015 06 16 0140-6736 352 9137 1998 Oct 24 Lancet (London, England) Lancet Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. 1347-51 Systolic hypertension increases the risk of dementia in elderly people. The vascular dementia project, set up in the framework of the double-blind (...) placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, investigated whether antihypertensive drug treatment could reduce the incidence of dementia. Eligible patients had no dementia, were at least 60 years old, and had a blood pressure when seated of 160-219 mm Hg systolic and below 95 mm Hg diastolic. Active treatment consisted of nitrendipine (10-40 mg/day) with the possible addition of enalapril (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs, titrated or combined

Lancet1998

1090. Randomised trial of management of hypertensive pregnancies by Korotkoff phase IV or phase V.

Randomised trial of management of hypertensive pregnancies by Korotkoff phase IV or phase V. 9737283 1998 09 17 1998 09 17 2015 06 16 0140-6736 352 9130 1998 Sep 05 Lancet (London, England) Lancet Randomised trial of management of hypertensive pregnancies by Korotkoff phase IV or phase V. 777-81 There is debate about whether diastolic blood pressure should be recorded as the fourth (muffling, K4) or fifth (disappearance, K5) Korotkoff sound in pregnancy. We compared maternal and fetal outcomes (...) and the likelihood that episodes of severe hypertension would be recorded when hypertensive pregnancies were managed according to either K4 or K5. 220 pregnant women with diastolic hypertension (K4 > or =90 mm Hg) after the 20th week of gestation were enrolled in a prospective randomised study at two obstetric units in Australia; they were randomly assigned management with K4 (n=103) or K5 (n=117) for the remainder of the pregnancy. Clinical management was according to a uniform department protocol. Analysis

Lancet1998

1091. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.

Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. 9791144 1998 10 29 1998 10 29 2014 11 20 0028-4793 339 18 1998 Oct 29 The New England journal of medicine N. Engl. J. Med. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. 1285-92 Angiotensin-converting-enzyme (ACE) inhibitors not only decrease the production (...) of angiotensin II but also decrease the degradation of bradykinin. In this study, a specific bradykinin-receptor antagonist, icatibant acetate (HOE 140), was used to determine the contribution of bradykinin to the short-term effects of ACE inhibition on blood pressure and plasma renin activity in both normotensive and hypertensive subjects. We compared the hemodynamic, renal, and endocrine effects of captopril alone (25 mg), captopril plus icatibant (100 microg per kilogram of body weight), the angiotensin

NEJM1998

1092. Effect of an aerobic exercise program on blood pressure and catecholamines in normotensive and hypertensive subjects.

Effect of an aerobic exercise program on blood pressure and catecholamines in normotensive and hypertensive subjects. 9033814 1997 03 20 1997 03 20 2016 10 18 0100-879X 29 5 1996 May Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas Braz. J. Med. Biol. Res. Effect of an aerobic exercise program on blood pressure and catecholamines in normotensive and hypertensive subjects. 633-7 Interrelations between physical exercise, monoamines (...) and hypertension are postulated by various investigators. The purpose of the present study was to determine and compare catecholamine levels at rest and after a 12-week aerobic exercise program in 11 sedentary normotensive (N) and 8 hypertensive (H) men. Plasma catecholamines were determined by high performance liquid chromatography with electrochemical detection. A significant post-exercise increase in plasma noradrenaline was observed in the N and H groups (P < 0.01) both before and after the aerobic

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas1997

1093. Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis

Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis Ross S D, Kupelnick B, Kumashiro M, Arellano F M, Mohanty N, Allen I E Authors' objectives The overall objective was to assess the risk of serious events associated with the use of any formulation of isradipine (...) as monotherapy in hypertension. The specific questions were: 1) Are the major adverse event rates higher with isradipine or isradipine sustained-release than with placebo or active controls? 2) Are the rates of withdrawal due to major adverse events higher with isradipine/isradipine sustained-release than with placebo or active controls? 3) What is the association of isradipine formulations with major adverse events? 4) Are the major adverse event rates from the sponsor's unpublished trials similar

DARE.1997

1094. Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension

Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension Malik A S, Warshafsky S, Lehrman S Authors' objectives Assess the magnitude and consistency of the effect of nifedipine on reducing pulmonary artery pressure (PAP) in patients with pulmonary hypertensive disorders. Searching MEDLINE was searched from 1966 (...) to 1995 using the keywords field for the combination 'nifedipine' and 'pulmonary hypertension'. Bibliographies of retrieved articles were also reviewed. Study selection Study designs of evaluations included in the review Case series were included. Specific interventions included in the review Nifedipine (30 to more than 200 mg/day). Participants included in the review Patients with the following illnesses were included in the analysis: pulmonary hypertension secondary to

DARE.1997

1095. Does medical treatment of mild intraocular hypertension prevent glaucoma?

Does medical treatment of mild intraocular hypertension prevent glaucoma? Does medical treatment of mild intraocular hypertension prevent glaucoma? Does medical treatment of mild intraocular hypertension prevent glaucoma? Aguinaga Ontoso I, Guillen Grima F, Aguinaga Ontoso E, Fernandez L R Authors' objectives To assess if treatment of mild or moderate intraocular hypertension can prevent glaucoma. Searching MEDLINE was searched on CD ROM between 1967 and 1995 using the keywords 'glaucoma (...) is limited to follow-up. The synthesis of data is appropriate but the authors choose to focus their discussion on a single treatment and there are no tests for heterogeneity. Bibliographic details Aguinaga Ontoso I, Guillen Grima F, Aguinaga Ontoso E, Fernandez L R. Does medical treatment of mild intraocular hypertension prevent glaucoma? European Journal of Epidemiology 1997; 13(1): 19-23 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Glaucoma /prevention & Humans; Ocular Physiological

DARE.1997

1096. Safety of nifedipine in patients with hypertension: a meta-analysis

Safety of nifedipine in patients with hypertension: a meta-analysis Safety of nifedipine in patients with hypertension: a meta-analysis Safety of nifedipine in patients with hypertension: a meta-analysis Stason W B, Schmid C H, Niedzwiecki D, Whiting G W, Caubet J-F, Luo D, Ross S D, Chalmers T C Authors' objectives To compare cardiovascular event rates in patients with mild or moderate hypertension who received nifedipine with active drug controls. Searching MEDLARS was searched from 1966 (...) to August 1995 using the MeSH 'hypertension' and 'nifedipine' as a textword. Studies published in English, French, Italian, German or Spanish were included. Current Contents (CD-ROM), and the bibliographies of retrieved articles were also searched. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included if they had a minimum of 10 patients, were published in a peer-reviewed journal or supplement to such a journal, and reported adverse events

DARE.1997

1097. Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn

Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn Hoffman G M, Ross G A, Day S E, Rice T B, Nelin L D Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with a gestational age of more than 35

NHS Economic Evaluation Database.1997

1098. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients

A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients (...) Milne R J, Hoorn S V, Jackson R T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two beta-blocker strategies (Celiprolol andAtenolol) for reducing cardiovascular risk in patients with mild-to-moderate hypertension were studied

NHS Economic Evaluation Database.1997

1099. Impact of new treatments for neonatal pulmonary hypertension on extracorporeal membrane oxygenation use and outcome

Impact of new treatments for neonatal pulmonary hypertension on extracorporeal membrane oxygenation use and outcome Impact of new treatments for neonatal pulmonary hypertension on extracorporeal membrane oxygenation use and outcome Impact of new treatments for neonatal pulmonary hypertension on extracorporeal membrane oxygenation use and outcome Kennaugh J M, Kinsella J P, Abman S H, Hernandez J A, Moreland S G, Rosenberg A A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology studied was extracorporeal membrane oxygenation (ECMO) which is used to treat newborns with persistent pulmonary hypertension (PPHN) and its associated outcomes, both with and without the prior use

NHS Economic Evaluation Database.1997

1100. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. 9297994 1997 10 14 1997 10 14 2015 06 16 0140-6736 350 9080 1997 Sep 13 Lancet (London, England) Lancet Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. 757-64 (...) Isolated systolic hypertension occurs in about 15% of people aged 60 years or older. In 1989, the European Working Party on High Blood Pressure in the Elderly investigated whether active treatment could reduce cardiovascular complications of isolated systolic hypertension. Fatal and non-fatal stroke combined was the primary endpoint. All patients (> 60 years) were initially started on masked placebo. At three run-in visits 1 month apart, their average sitting systolic blood pressure was 160-219 mm Hg

Lancet1997